University of Utah: Neoplasms trials
The registry lists 15 Neoplasms studies with University of Utah as lead sponsor. 4 are open to participants now and 5 have results posted.
Phase 1 2Phase 2 2Phase 3 1No phase 10(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- AI-Driven Survivorship Care Plans (AI-SCP)Not yet recruitingNCT07700199Not applicable
- SAFE.AI: Developing and Testing an AI-based Hybrid Chatbot for Financial Empowerment in Rural Cancer CareRecruitingNCT07410689Not applicable
- Enhancing Motivation to Quit Smoking Via Self-Help Intervention Targeted to Cancer TypeRecruitingNCT06484179Not applicable
- Improving Health Insurance Literacy Among Young Adult Cancer SurvivorsRecruitingNCT05829070Not applicable
- Broadening the Reach, Impact, and Delivery of Genetic ServicesCompletedNCT03985852Not applicableResults posted
- Smart-phone Application to Promote Medication Adherence in Adolescents and Young Adults (AYA) With CancerCompletedNCT01618344Results posted
- Multi-Tracer Positron Emission Tomography in Patients With Solid TumorsTerminatedNCT01243333Not applicableResults posted
- Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic MalignanciesCompletedNCT00795132Phase 2Results posted
- Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) PatientsTerminatedNCT00585221Phase 2Results posted
- PREVENT HPV -Related Cancers TrialActive, not recruitingNCT07217145Phase 3
- PREVENT Pilot HPV - Related Cancers TrialCompletedNCT06738355Not applicable
- Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the PandemicCompletedNCT04464486Not applicable
- Home-based HIIT to Improve CRC Survivorship: Feasibility and Relationship With Novel Surrogate Biomarkers of CRC RecurrenceCompletedNCT04080414Not applicable
- Apatinib With Pembrolizumab in Previously Treated Advanced MalignanciesTerminatedNCT03407976Phase 1
- Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic MalignanciesTerminatedNCT01818479Phase 1